seen from Hong Kong SAR China
seen from United States
seen from Ireland
seen from China
seen from Malaysia
seen from China
seen from Kazakhstan
seen from United Kingdom
seen from United States
seen from Maldives
seen from Australia
seen from China
seen from United States
seen from China
seen from Russia
seen from Brazil
seen from China
seen from United States
seen from United States
seen from China
Regorafenib - an inhibitor of tyrosine kinase (VEGFR - TIE2) for the treatment of metastatic colorectal cancer, unresectable hepatocellular carcinoma, and gastrointestinal stromal tumours. Its structure is closely related sorafenib with a Florine replacement.
Sorafenib - inhibitor of tyrosine protein kinases (VEGFR, PDGFR, and Raf kinases) for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and radioactive iodine resistant advanced thyroid carcinoma.
Antiangiogenic Cancer Therapy
C O N T E N T S:
KEY TOPICS
Data from late-stage clinical trials support the role of antiangiogenic agents in cancer therapy and the significant role that VEGF plays in angiogenesis.(More…)
POSSIBLY USEFUL
A phase III trial of the currently marketed monoclonal antibody to VEGF-A (referred to as VEGF), bevacizumab (Avastin), added to conventional cytotoxic chemotherapy showed greater survival in…
View On WordPress
